Sepsis continues to be a deadly malady that clinicians haven’t figured out how to tackle consistently. A major limitation of treatment is how early clinicians can identify that a patient is showing signs of sepsis.
Beckman Coulter just received FDA clearance for its Early Sepsis Indicator, a cellular biomarker for the company’s DxH 900 (Read more...)